Monterey Bio Acquisition Corporation
MTRY · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 275.18 | 1.71 | -0.38 | -0.66 |
| FCF Yield | -0.64% | -0.25% | -0.75% | -0.08% |
| EV / EBITDA | -149.79 | -156.91 | -110.67 | -165.19 |
| Quality | ||||
| ROIC | -1.71% | -1.64% | -2.35% | -4.31% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 2.25 | 0.87 | 1.26 | 0.29 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -156.74% | 65.76% | -218.97% | 28.08% |
| Safety | ||||
| Net Debt / EBITDA | -3.77 | -2.73 | 0.31 | 0.63 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |